U.S. veterans who served in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) face an increased risk of developing several chronic respiratory conditions, according to new research ...

Studies show that smell loss with age may reflect more serious underlying problems, and is even linked to how long we're ...

UK shares extended their rally on Tuesday, with the FTSE 100 rising 1.18% at closing and reaching a new all-time high during the session, amid fresh corporate updates and economic data. Retailer Next ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

Another common reason for nosebleeds is “digital manipulation, which is a nice way of saying nose picking or scratching your nose”, says Loftus. The nose is delicate, and even a light bump or scratch ...

(Alliance News) - Blue chips continued their strong start to the year on Tuesday with the FTSE 100 hitting a new record led by gains in retailer Next and drug stocks, GSK and AstraZeneca. The FTSE 100 ...

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...

The concept of saline nasal irrigation, or bathing the nasal passages with a saltwater solution, is thought to have been ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

After the fasting, the uncomfortable cleanse and a drowsy ride home, it’s a relief to have your colonoscopy screening behind you. But when the report arrives with the words “colon polyps,” some ...

The drug candidate utilizes a soft mist nasal spray delivery system and is currently in preclinical stages. "This letter of intent with Allucent could lead to a meaningful step forward in advancing ...